The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

By Noa Stanietsky, H. Šimić, Jurica Arapović, Amir Toporik, O. Levy, Amit Novik, Zurit Levine, Meirav Beiman, Liat Dassa, H. Achdout and 4 more. 2009

3,501 citations recorded by the source corpus.

Subfields: Immunology, Oncology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. J. Snyder-Cappione
2. Anna C. Belkina
3. A. Anderson
4. V. Kuchroo
5. W. Garrett
6. S. Jonjić

In Oncology

1. J. Snyder-Cappione
2. Anna C. Belkina
3. Douglas A. Lauffenburger
4. A. Anderson
5. V. Kuchroo
6. W. Garrett

Citations in the corpus

• Lag-3, Tim-3, and TIGIT co-inhibitory receptors with specialized functions in immune regulation (2016, background): “TIGIT binds two ligands, CD155 (PVR) and CD112 (PVRL2, nectin-2), which are expressed on APCs, T cells, and a variety of nonhematopoietic cell types including tumor cells (Casado et al., 2009; Levin et al., 2011; Mendelsohn et al., 1989; Stanietsky et al., 2009; Yu et al., 2009).”